RVT 501

Drug Profile

RVT 501

Alternative Names: E 6005; RVT-501

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; Roivant Sciences
  • Class Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 21 Dec 2016 Phase-II clinical trials in Atopic dermatitis (In adolescents, In adults, In the elderly) in USA (Topical)
  • 28 Oct 2016 Dermavant Sciences plans a phase II trial for Atopic dermatitis (In adolescents, In adults) in USA (Topical) (NCT02950922)
  • 20 Oct 2016 Adverse events and Pharmacokinetics data from a phase II trial in Atopic dermatitis and a phase I (in volunteers) trial released by Eisai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top